Pancreatic Cancer Research

ResearcherUniversity of Colorado AnschutzActive in the last 2 years

Jun Ishida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7550-448X; OpenAlex author ID A5049211889. Sources: OpenAlex.

Their work

Papers
20
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: 3 papers · 2024: 3 papers · 2025: 1 paper · 2026: 7 papers

Papers 20

  1. Learning Curve Effect in Reducing Local Recurrence Rate After Resection of Pancreatic Cancer With Arterial Abutment: A Single-Center Retrospective Study. Co-author DOI 10.1002/ags3.70100↗
  2. Timing of Adjuvant S-1 Chemotherapy and Survival After Pancreatectomy for Pancreatic Cancer: An Ancillary Analysis of the JASPAC 01 Trial. Co-author DOI 10.1002/jhbp.70117↗
  3. Intraoperative frozen section analysis of the portal or superior mesenteric vein transection margin in pancreatectomy with venous resection for pancreatic canc… Co-author DOI 10.1016/j.gassur.2026.102410↗
  4. Incidence and consequences of chyle leak after pancreatectomy for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2025.10.004↗
  5. Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer. Co-author DOI 10.1245/s10434-025-18491-3↗
  6. ASO Visual Abstract: Short- and Long-Term Outcomes after Pancreatectomy for Pancreatic Cancer in Patients with Prior Esophagectomy for Esophageal Cancer. Co-author DOI 10.1245/s10434-025-18718-3↗
  7. Delayed Initiation of S-1 Adjuvant Chemotherapy Impairs Survival in Patients With Curatively Resected Pancreatic Cancer. Co-author DOI 10.21873/anticanres.18004↗
  8. Prognostic Significance of GLIM-Defined Malnutrition in Patients With Resectable Pancreatic Adenocarcinoma Following Upfront Surgery. Co-author DOI 10.1002/ags3.70059↗
  9. Preoperative level of serum transthyretin as a novel biomarker predicting survival in resected pancreatic ductal adenocarcinoma with neoadjuvant therapy. Co-author DOI 10.1016/j.pan.2024.07.012↗
  10. Characteristics and prognosis of patients with pancreatic adenocarcinoma not expressing CA19-9: Analysis of the National Cancer Database. Co-author DOI 10.1016/j.pan.2024.11.011↗
  11. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma: An Updated Nationwide Study. Co-author DOI 10.1097/sla.0000000000005925↗
  12. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy. Co-author DOI 10.1001/jamaoncol.2022.5808↗
  13. Clinicopathological variables and risk factors for lung recurrence after resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.asjsur.2022.03.043↗
  14. Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: a retrospective study. Co-author DOI 10.1186/s13014-023-02301-9↗
  15. [A Patient with Ascending Jejunal Mesentery Metastasis of Pancreatic Cancer after a Subtotal Stomach-Preserving Pancreaticoduodenectomy]. Co-author PMID 35045476↗
  16. [A Case of Pancreatic Cancer with Gastric Wall Recurrence after Laparoscopic Distal Pancreatectomy Due to Needle Tract Seeding following EUS-FNA]. Co-author PMID 35045477↗
  17. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophi… Co-author DOI 10.1007/s00595-015-1206-3↗
  18. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-014-4280-7↗
  19. [A case of adjuvant surgery for a patient with initially unresectable locally advanced pancreatic cancer (LAPC) with a favorable response to S-1 chemotherapy]. Co-author PMID 25731462↗
  20. [A case of metachronous pancreatic cancer that developed 4 years after initial pancreatectomy]. Co-author PMID 24393957↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hirochika Toyama · 14 shared papers, 2014–2026 · strength 2.45
  2. Takumi Fukumoto · 15 shared papers, 2013–2026 · strength 2.44
  3. Yoshihide Nanno · 10 shared papers, 2014–2026 · strength 2.23
  4. Hiroaki Yanagimoto · 10 shared papers, 2021–2026 · strength 2.11
  5. Takuya Mizumoto · 8 shared papers, 2024–2026 · strength 2.03
  6. Sadaki Asari · 13 shared papers, 2013–2026 · strength 1.99
  7. Dongha Lee · 5 shared papers, 2025–2026 · strength 1.27
  8. Toshitaka Sugawara · 4 shared papers, 2023–2026 · strength 0.84
  9. Samuele Grandi · 4 shared papers, 2023–2026 · strength 0.84
  10. Richard David Schulick · 4 shared papers, 2023–2026 · strength 0.84
  11. Oskar Franklin · 3 shared papers, 2024–2026 · strength 0.67
  12. Ana Gleisner · 3 shared papers, 2023–2024 · strength 0.56
  13. Marco Del Chiaro · 3 shared papers, 2023–2024 · strength 0.56
  14. Yuta Ogura · 3 shared papers, 2021–2023 · strength 0.37
  15. Ippei Matsumoto · 5 shared papers, 2013–2023 · strength 0.31
  16. Sachiyo Shirakawa · 3 shared papers, 2015–2023 · strength 0.30
  17. Akira Fukutomi · 1 shared paper, 2026 · strength 0.29
  18. Dongha Lee · 1 shared paper, 2026 · strength 0.29
  19. Narikazu Boku · 1 shared paper, 2026 · strength 0.29
  20. Naoto Gotohda · 1 shared paper, 2026 · strength 0.29
  21. Takayuki Kodama · 1 shared paper, 2026 · strength 0.29
  22. Katsuhiko Uesaka · 1 shared paper, 2026 · strength 0.29
  23. Marco Del Chiaro · 1 shared paper, 2026 · strength 0.28
  24. Andrii Khomiak · 1 shared paper, 2026 · strength 0.28
  25. Thomas F. Stoop · 1 shared paper, 2026 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.